Skip NavigationSkip to Content

Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP EGFR Mutant Non-small-cell Lung Cancer Growing in the Brain of Nude Mice

  1. Author:
    Katsuya, Yuki
    Miyake, Kentaro
    Higuchi, Takashi
    Oshiro, Hiromichi
    Sugisawa, Norihiko
    Singh,Shree Ram
    Goto, Yasushi
    Zhao, Ming
    Hoffman, Robert M.
  2. Author Address

    AntiCancer Inc, 7917 Ostrow St, San Diego, CA 92111 USA.Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.NCI, Basic Res Lab, Ctr Canc Res, Frederick, MD 21702 USA.Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan.
    1. Year: 2020
    2. Date: May-Jun
  1. Journal: In vivo (Athens, Greece)
  2. INT INST ANTICANCER RESEARCH,
    1. 34
    2. 3
    3. Pages: 1027-1030
  3. Type of Article: Article
  4. ISSN: 0258-851X
  1. Abstract:

    Background/Aim: Brain metastases are found in approximately 30% of patients with epidermal-growth-factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). We compared the efficacy of two EGFR-tyrosine kinase inhibitors (TKIs), erlotinib and osimertinib on a PC9-GFP EGFR mutant NSCLC growing in the brain of nude mice. Materials and Methods: The brain metastasis models were randomized into five groups and treated for 15 days: Control; 5 mg/kg erlotinib; 50 mg/kg erlotinib; 0.5 mg/kg osimertinib; 5 mg/kg osimertinib. Tumor volume was evaluated by non-invasive fluorescence imaging. Results: Only 5 mg/kg osimertinib, a low-dose compared to the clinically-equivalent dose, showed significant tumor regression compared to the control. Conclusion: This study strongly supports the high activity of osimertinib for intracranial lesions of EGFR-mutant NSCLC.

    See More

External Sources

  1. DOI: 10.21873/invivo.11871
  2. PMID: 32354888
  3. WOS: 000530682800009

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel